Ankündigung • May 26
Vineet Laboratories Limited to Report Q4, 2026 Results on May 30, 2026 Vineet Laboratories Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 30, 2026 Buy Or Sell Opportunity • May 13
Now 23% undervalued Over the last 90 days, the stock has risen 13% to ₹34.65. The fair value is estimated to be ₹45.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 46% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Feb 15
Third quarter 2026 earnings released: EPS: ₹0.92 (vs ₹6.19 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹0.92 (up from ₹6.19 loss in 3Q 2025). Revenue: ₹157.0m (down 13% from 3Q 2025). Net income: ₹8.51m (up ₹65.6m from 3Q 2025). Profit margin: 5.4% (up from net loss in 3Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 10
Vineet Laboratories Limited to Report Q3, 2026 Results on Feb 14, 2026 Vineet Laboratories Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026 Ankündigung • Feb 07
Vineet Laboratories Limited Approves Appointment of Jasmin Kunal Tailor as Independent Director Vineet Laboratories Limited at its EGM held on February 7, 2026, approved the appointment of Jasmin Kunal Tailor (DIN:10794164) as an Independent Director of Company. New Risk • Feb 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 88% per year over the past 5 years. Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Market cap is less than US$10m (₹657.2m market cap, or US$7.26m). New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 88% per year over the past 5 years. Market cap is less than US$10m (₹358.7m market cap, or US$4.01m). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Significant insider selling over the past 3 months (₹20m sold). Ankündigung • Nov 28
Vineet Laboratories Limited has filed a Follow-on Equity Offering in the amount of INR 300 million. Vineet Laboratories Limited has filed a Follow-on Equity Offering in the amount of INR 300 million.
Security Name: Equity Shares
Security Type: Common Stock
Transaction Features: Rights Offering Ankündigung • Nov 08
Vineet Laboratories Limited Announces Resignation of Hari Priya Yerukalapudi as Independent Director, Effective November 08, 2025 Vineet Laboratories Limited at its board meeting held on November 08, 2025, noted the resignation of Ms Hari Priya Yerukalapudi from the office of Independent Director with effect from the close of business hours of November 08, 2025, because of change in her professional priorities and family necessities. Ankündigung • Nov 04
Vineet Laboratories Limited to Report Q2, 2026 Final Results on Nov 08, 2025 Vineet Laboratories Limited announced that they will report Q2, 2026 final results at 12:08 PM, Indian Standard Time on Nov 08, 2025 Ankündigung • Oct 13
Vineet Laboratories Limited to Report Q2, 2026 Results on Oct 23, 2025 Vineet Laboratories Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Oct 23, 2025 Recent Insider Transactions • Sep 30
Founder recently sold ₹3.6m worth of stock On the 23rd of September, Gaddam Ramana sold around 100k shares on-market at roughly ₹35.92 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹5.0m. Gaddam has been a net seller over the last 12 months, reducing personal holdings by ₹20m. Recent Insider Transactions • Sep 03
Founder recently sold ₹2.4m worth of stock On the 29th of August, Gaddam Ramana sold around 70k shares on-market at roughly ₹33.72 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹5.0m. Gaddam has been a net seller over the last 12 months, reducing personal holdings by ₹14m. Ankündigung • Sep 02
Vineet Laboratories Limited, Annual General Meeting, Sep 25, 2025 Vineet Laboratories Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Recent Insider Transactions • Aug 30
CFO & Whole-time Director recently sold ₹1.5m worth of stock On the 22nd of August, Satyanarayana Bhupathiraju sold around 42k shares on-market at roughly ₹35.17 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.0m. Satyanarayana has been a net seller over the last 12 months, reducing personal holdings by ₹6.8m. Recent Insider Transactions • Aug 19
Founder recently sold ₹5.0m worth of stock On the 11th of August, Gaddam Ramana sold around 150k shares on-market at roughly ₹33.40 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Gaddam has been a net seller over the last 12 months, reducing personal holdings by ₹11m. Recent Insider Transactions • Aug 12
CFO & Whole-time Director recently sold ₹637k worth of stock On the 5th of August, Satyanarayana Bhupathiraju sold around 19k shares on-market at roughly ₹34.03 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.1m. Satyanarayana has been a net seller over the last 12 months, reducing personal holdings by ₹3.5m. Reported Earnings • Jul 25
First quarter 2026 earnings released: ₹0.94 loss per share (vs ₹2.31 loss in 1Q 2025) First quarter 2026 results: ₹0.94 loss per share (improved from ₹2.31 loss in 1Q 2025). Revenue: ₹74.6m (down 69% from 1Q 2025). Net loss: ₹8.66m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Ankündigung • Jul 15
Vineet Laboratories Limited to Report Q1, 2026 Results on Jul 22, 2025 Vineet Laboratories Limited announced that they will report Q1, 2026 results on Jul 22, 2025 Recent Insider Transactions • Jul 01
Insider recently sold ₹1.5m worth of stock On the 23rd of June, Alluri Mythili sold around 50k shares on-market at roughly ₹29.41 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.1m. Insiders have been net sellers, collectively disposing of ₹23m more than they bought in the last 12 months. Recent Insider Transactions • Jun 27
Non-Executive Director recently sold ₹1.4m worth of stock On the 20th of June, Alluri Raju sold around 50k shares on-market at roughly ₹28.92 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.1m. Insiders have been net sellers, collectively disposing of ₹18m more than they bought in the last 12 months. Recent Insider Transactions • May 30
Founder recently sold ₹2.2m worth of stock On the 26th of May, Gaddam Ramana sold around 70k shares on-market at roughly ₹32.10 per share. This transaction amounted to 5.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.1m. This was Gaddam's only on-market trade for the last 12 months. Reported Earnings • May 14
Full year 2025 earnings released: ₹21.90 loss per share (vs ₹1.11 profit in FY 2024) Full year 2025 results: ₹21.90 loss per share (down from ₹1.11 profit in FY 2024). Revenue: ₹769.8m (down 49% from FY 2024). Net loss: ₹201.9m (down ₹212.2m from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 18
Third quarter 2025 earnings released: ₹6.19 loss per share (vs ₹2.24 loss in 3Q 2024) Third quarter 2025 results: ₹6.19 loss per share (further deteriorated from ₹2.24 loss in 3Q 2024). Revenue: ₹181.3m (down 45% from 3Q 2024). Net loss: ₹57.1m (loss widened 176% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 04
Vineet Laboratories Limited to Report Q3, 2025 Results on Feb 12, 2025 Vineet Laboratories Limited announced that they will report Q3, 2025 results on Feb 12, 2025 New Risk • Jan 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.01x net interest cover). Earnings have declined by 23% per year over the past 5 years. Market cap is less than US$10m (₹482.7m market cap, or US$5.60m). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Board Change • Nov 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Hari Yerukalapudi was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 15
Second quarter 2025 earnings released: ₹1.98 loss per share (vs ₹2.62 profit in 2Q 2024) Second quarter 2025 results: ₹1.98 loss per share (down from ₹2.62 profit in 2Q 2024). Revenue: ₹195.3m (down 55% from 2Q 2024). Net loss: ₹18.3m (down 176% from profit in 2Q 2024). Ankündigung • Nov 13
Vineet Laboratories Limited Announces Resignation of Bhaskara Reddy Karna as Independent Director Vineet Laboratories Limited announced resignation of Bhaskara Reddy Karna from the office of independent director with effect from November 13, 2024. Reason: No material reasons for the resignation. Ankündigung • Nov 06
Vineet Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Vineet Laboratories Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Ankündigung • Sep 04
Vineet Laboratories Limited, Annual General Meeting, Sep 27, 2024 Vineet Laboratories Limited, Annual General Meeting, Sep 27, 2024. Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹2.31 loss per share (vs ₹1.36 loss in 1Q 2024) First quarter 2025 results: ₹2.31 loss per share (further deteriorated from ₹1.36 loss in 1Q 2024). Revenue: ₹242.3m (down 35% from 1Q 2024). Net loss: ₹21.3m (loss widened 71% from 1Q 2024). Ankündigung • Jul 31
Vineet Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024 Vineet Laboratories Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹66.10, the stock trades at a trailing P/E ratio of 59.3x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total loss to shareholders of 37% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹1.11 (vs ₹1.36 in FY 2023) Full year 2024 results: EPS: ₹1.11 (down from ₹1.36 in FY 2023). Revenue: ₹1.51b (down 29% from FY 2023). Net income: ₹10.3m (down 18% from FY 2023). Profit margin: 0.7% (up from 0.6% in FY 2023). The increase in margin was driven by lower expenses. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Market cap is less than US$10m (₹516.3m market cap, or US$6.21m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change). Ankündigung • May 23
Vineet Laboratories Limited to Report Q4, 2024 Results on May 29, 2024 Vineet Laboratories Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹57.45, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past year. Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹2.22 loss per share (vs ₹1.51 profit in 3Q 2023) Third quarter 2024 results: ₹2.22 loss per share (down from ₹1.51 profit in 3Q 2023). Revenue: ₹327.0m (down 51% from 3Q 2023). Net loss: ₹20.7m (down 248% from profit in 3Q 2023). Ankündigung • Feb 03
Vineet Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024 Vineet Laboratories Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹81.65, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to ₹69.15, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 20% over the past year. New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹626.4m market cap, or US$7.52m). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹2.62 (vs ₹5.10 loss in 2Q 2023) Second quarter 2024 results: EPS: ₹2.62 (up from ₹5.10 loss in 2Q 2023). Revenue: ₹433.9m (up 9.8% from 2Q 2023). Net income: ₹24.2m (up ₹71.2m from 2Q 2023). Profit margin: 5.6% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Ankündigung • Nov 11
Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer Vineet Laboratories Limited Appointed of Mr. Rameshkumar Bandari as the Company Secretary and Compliance Officer with effect from November 10, 2023 at a remuneration of INR 25,000 per month. brief Profile: Educational Qualification: · Bachelors in Commerce from Osmania University · Associate Company Secretary from the Institute of Company Secretaries of India. · Bachelor in Law from the Osmania University Experience: Total 13 years of experience as a Company Secretary of Private and Listed Companies. Ankündigung • Nov 04
Vineet Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023 Vineet Laboratories Limited announced that they will report Q2, 2024 results on Nov 10, 2023 Ankündigung • Oct 29
Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company Vineet Laboratories Limited informed that Ms. Nirosha Ravikanti, Associate member of the Institute of Company Secretaries of India, having Membership No: A68115, has resigned as Company Secretary and Compliance Officer of the Company with effect from closing business hours of October 28, 2023 due to personal reasons. Ankündigung • Oct 18
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer Vineet Laboratories Limited announced that the Board of Directors of the company in its meeting held on October 16, 2023 has approved the appointment of Mr. Satish Pandurang Samant as Chief Executive Officer (CEO) of the Company effective October 16, 2023 for a period of 3 years. Educational Qualification: M.Sc in Organic Chemistry Ph.D in Synthetic Organic Chemistry and Asymmetric Induction. Experience: Total 37 years of experience in API Intermediaries, Pharma and Chemicals industry. Ankündigung • Oct 17
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as an Additional Executive Director Vineet Laboratories Limited announced that the Board of Directors of the company in its meeting held on October 16, 2023 has approved the appointment of Mr. Satish Pandurang Samant as an Additional Executive Director and Chief Executive Officer (CEO) of the Company effective October 16, 2023 for a period of 3 years. Educational Qualification: M.Sc in Organic Chemistry Ph.D in Synthetic Organic Chemistry and Asymmetric Induction. Experience: Total 37 years of experience in API Intermediaries, Pharma and Chemicals industry. Ankündigung • Sep 06
Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2023 Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2023, at 09:30 Indian Standard Time. Location: Minerva Coffee Shop, 3rd Floor, Beside Sanjeevini Hospital, Kiran Nagar, Doctors' Colony, Kothapet, Hyderabad, Telangana 500 035 Telangana India Agenda: To receive, consider, and adopt the Audited Financial Statements for the financial year ended March 31, 2023; to appoint Mr. Gaddam Venkata Ramana, who retires by rotation as a director; to ratify the remuneration of Cost Auditors for the financial year 2023-24; to approve existing as well as new material related party transactions with Organo Metallics Private Limited; and to consider other matters. Ankündigung • Aug 13
Vineet Laboratories Limited Announces Board Changes Vineet Laboratories Limited announced that at the board meeting held on August 12, 2023, the company approved the appointment of Mr. Alluri Ranga Raju as Additional non executive director. Resignation of Mr. Kandula Murali Mohan as whole time director with effect from August 12, 2023. Mr. Alluri Ranga Raju has total 20 years of experience in Infrastructure, Realty Construction business. New Risk • Aug 13
New major risk - Revenue and earnings growth Earnings have declined by 2.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 97% Paying a dividend despite having no free cash flows. Earnings have declined by 2.8% per year over the past 5 years. Market cap is less than US$10m (₹523.2m market cap, or US$6.31m). Reported Earnings • Aug 13
First quarter 2024 earnings released: ₹1.36 loss per share (vs ₹1.10 profit in 1Q 2023) First quarter 2024 results: ₹1.36 loss per share (down from ₹1.10 profit in 1Q 2023). Revenue: ₹375.5m (down 23% from 1Q 2023). Net loss: ₹12.5m (down 224% from profit in 1Q 2023). Valuation Update With 7 Day Price Move • Aug 09
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹60.75, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 4.1% over the past year. Ankündigung • Aug 05
Vineet Laboratories Limited to Report Q1, 2024 Results on Aug 12, 2023 Vineet Laboratories Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 12, 2023 Reported Earnings • May 31
Full year 2023 earnings released: EPS: ₹1.36 (vs ₹7.20 in FY 2022) Full year 2023 results: EPS: ₹1.36 (down from ₹7.20 in FY 2022). Revenue: ₹2.12b (up 11% from FY 2022). Net income: ₹12.5m (down 81% from FY 2022). Profit margin: 0.6% (down from 3.5% in FY 2022). The decrease in margin was driven by higher expenses. Ankündigung • May 19
Vineet Laboratories Limited to Report Q4, 2023 Results on May 29, 2023 Vineet Laboratories Limited announced that they will report Q4, 2023 results on May 29, 2023 Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹49.40, the stock trades at a trailing P/E ratio of 46.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 32% over the past year. Recent Insider Transactions • Apr 03
MD & Director recently bought ₹333k worth of stock On the 28th of March, Gaddam Ramana bought around 8k shares on-market at roughly ₹41.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹7.4m. Gaddam has been a buyer over the last 12 months, purchasing a net total of ₹8.1m worth in shares. Recent Insider Transactions • Mar 30
MD & Director recently bought ₹416k worth of stock On the 23rd of March, Gaddam Ramana bought around 10k shares on-market at roughly ₹41.62 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹7.4m. Gaddam has been a buyer over the last 12 months, purchasing a net total of ₹8.2m worth in shares. Recent Insider Transactions • Mar 26
MD & Director recently bought ₹868k worth of stock On the 21st of March, Gaddam Ramana bought around 20k shares on-market at roughly ₹43.41 per share. This transaction amounted to 2.5% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹7.4m. Gaddam has been a buyer over the last 12 months, purchasing a net total of ₹8.7m worth in shares. Recent Insider Transactions • Mar 16
MD & Director recently bought ₹430k worth of stock On the 8th of March, Gaddam Ramana bought around 10k shares on-market at roughly ₹42.99 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Gaddam's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹43.35, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 21% over the past year. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹1.51 (vs ₹3.52 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.51 (down from ₹3.52 in 3Q 2022). Revenue: ₹667.7m (up 20% from 3Q 2022). Net income: ₹13.9m (down 57% from 3Q 2022). Profit margin: 2.1% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Ankündigung • Feb 07
Vineet Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023 Vineet Laboratories Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Feb 14, 2023 Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improved over the past week After last week's 17% share price gain to ₹63.25, the stock trades at a trailing P/E ratio of 61.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total loss to shareholders of 22% over the past year. Reported Earnings • Nov 20
Second quarter 2023 earnings released: ₹5.10 loss per share (vs ₹3.52 profit in 2Q 2022) Second quarter 2023 results: ₹5.10 loss per share (down from ₹3.52 profit in 2Q 2022). Revenue: ₹395.1m (down 29% from 2Q 2022). Net loss: ₹47.0m (down 243% from profit in 2Q 2022). Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Bhaskara Karna is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 02
First quarter 2023 earnings released: EPS: ₹1.10 (vs ₹2.18 in 1Q 2022) First quarter 2023 results: EPS: ₹1.10 (down from ₹2.18 in 1Q 2022). Revenue: ₹489.1m (down 80% from 1Q 2022). Net income: ₹10.1m (down 43% from 1Q 2022). Profit margin: 2.1% (up from 0.7% in 1Q 2022). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improved over the past week After last week's 22% share price gain to ₹65.00, the stock trades at a trailing P/E ratio of 9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 16% share price gain to ₹58.85, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Bhaskara Karna is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improved over the past week After last week's 26% share price gain to ₹68.55, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Board Change • Mar 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Bhaskara Karna is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
